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Peter R. Kowey, MD; Paul Dorian, MD; L. Brent Mitchell, MD; Craig M. Pratt, MD; Denis Roy, MD;
Peter J. Schwartz, MD; Jerzy Sadowski, MD, PhD; Dorota Sobczyk, MD; Andrzej Bochenek, MD, PhD;
Egon Toft, MD; for the Atrial Arrhythmia Conversion Trial Investigators
Background—Postoperative atrial arrhythmias are common and are associated with considerable morbidity. This study
was designed to evaluate the efficacy and safety of vernakalant for the conversion of atrial fibrillation (AF) or atrial
flutter (AFL) after cardiac surgery.
Methods and Results—This was a prospective, randomized, double-blind, placebo-controlled trial of vernakalant for the
conversion of AF or AFL after coronary artery bypass graft, valvular surgery, or both. Patients were randomly assigned
2:1 to receive a 10-minute infusion of 3 mg/kg vernakalant or placebo. If AF or AFL was present after a 15-minute
observation period, then a second 10-minute infusion of 2 mg/kg vernakalant or placebo was given. The primary end
point was the conversion of postcardiac surgery AF or AFL to sinus rhythm within 90 minutes of dosing. In patients
with AF, 47 of 100 (47%) who received vernakalant converted to SR compared with 7 of 50 (14%) patients who
received placebo (P0.001). The median time to conversion was 12 minutes. Vernakalant was not effective in
converting postoperative AFL to sinus rhythm. Two serious adverse events occurred within 24 hours of vernakalant
administration (hypotension and complete atrioventricular block). There were no cases of torsades de pointes, sustained
ventricular tachycardia, or ventricular fibrillation. There were no deaths.
Conclusions—Vernakalant was safe and effective in the rapid conversion of AF to sinus rhythm in patients who had AF
after cardiac surgery.
Clinical Trial Registration—clinicaltrials.gov. Identifier: NCT00125320.
(Circ Arrhythm Electrophysiol. 2009;2:652-659.)
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Atrial arrhythmias occur after coronary artery bypass graft(CABG) and valvular surgery in approximately 20% to
50% of patients, depending on definitions, types of surgery,
and surveillance methods.1–3 Atrial fibrillation (AF) is the
most common atrial arrhythmia in this setting.4–6 Postopera-
tive atrial arrhythmias are associated with increased morbid-
ity from stroke, congestive heart failure, hemodynamic com-
promise, and ventricular dysrhythmias and with prolonged
hospitalization and increased costs and rates of rehospitaliza-
tion after discharge.1,7–10
Clinical Perspective on p 659
Current treatment strategies for post–cardiac surgery AF
are similar to those for acute AF and consist of thrombosis
prevention and various agents to control ventricular response
rate and restore sinus rhythm (SR).2,11–13 Currently available
antiarrhythmic drugs have variable efficacy and safety pro-
files and may produce significant cardiac and noncardiac
adverse effects. They may be contraindicated in some post-
operative patients because of their negative inotropic or
chronotropic effects.11,14 A safe and effective agent for the
rapid conversion of atrial arrhythmias to SR would benefit
patients after cardiac surgery.
Vernakalant hydrochloride injection (RSD1235) is a novel,
relatively atrial-selective antiarrhythmic agent for the conver-
sion of AF to SR that acts by means of frequency-dependent
blockade of Na channels as well as blockade of early-
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activating K channels.15 In a placebo-controlled phase 2 trial
(n56), vernakalant rapidly converted recent-onset AF (last-
ing 3 to 72 hours) to SR.16 In addition, 2 recent placebo-
controlled, phase 3 clinical studies have confirmed the
efficacy and safety of vernakalant in converting recent-onset
AF (lasting 3 hours to 7 days) to SR.17,18 The rate of
conversion of AF to atrial flutter (AFL) in these nonsurgical
populations was low (5.6% and 8.6% in the phase 2 and 3
trials, respectively).16,17 This study evaluated the efficacy of
vernakalant in converting AF or AFL to SR in patients
recovering from CABG, valvular surgery, or both.
Methods
Study Design
This was a phase 3, prospective, randomized, double-blind, placebo-
controlled study conducted at 43 sites in Canada, the United States,
Denmark, Italy, Poland, Argentina, and India. The study was
approved by an institutional review board at each site, and all
patients gave written informed consent.
Randomization codes were generated by an unblinded statistician
who was not involved in the study operations. The unblinded
pharmacist or designee at each site randomly assigned eligible
patients by calling a central randomization center. All of the study
staff, with the exception of the site pharmacist, were blinded to the
identity of the treatment assignments. The pharmacist at each site
prepared study drug or placebo as required and ensured that the
volume of study treatment and the time for delivery to study
personnel was equivalent, regardless of treatment assignment.
Eligible patients included men and women 18 years of age, with
sustained AF or AFL (lasting 3 to 72 hours) occurring between 24
hours and 7 days after CABG, valvular surgery, or both. Patients
were hemodynamically stable (systolic blood pressure [SBP]
90 mm Hg and 160 mm Hg and diastolic blood pressure
95 mm Hg), weighed 45 to 136 kg (99 to 300 lb), and had
documented SR before and after surgery. Women were not pregnant
or nursing, and, if premenopausal, were using an effective form of
birth control. Patients were excluded if they had an uncorrected QT
interval 500 ms; a ventricular response rate to AF 45 bpm; a
QRS interval140 ms without a pacemaker; second- or third-degree
atrioventricular (AV) block; a history of torsades de pointes; unstable
class IV congestive heart failure; serious hepatic or renal disease;
end-stage disease states; a reversible cause of AF such as hyperthy-
roidism or pulmonary embolism; an uncorrected electrolyte imbal-
ance; digoxin toxicity; or had received another investigational drug
or intravenous vernakalant in the 30 days before enrollment. Patients
were excluded if oral amiodarone had been taken in the previous 3
months, if intravenous amiodarone had been administered in the
previous 24 hours, or if class I or class III antiarrhythmic drugs had
been administered after cardiac surgery. Treatment with rate control
drugs, such as -adrenergic–blocking agents, calcium antagonists, or
digoxin, was permitted provided heart rate (HR) was 50 bpm and
that a loading dose or bolus supplementation of the agent was not
given in the 2 hours before study drug administration.
Patients were randomly assigned 2:1 to receive either a 10-minute
infusion of 3.0 mg/kg vernakalant or placebo (normal saline solu-
tion), followed by a 15-minute observation period. If the patient did
not demonstrate conversion to SR, a second 10-minute infusion of
2.0 mg/kg vernakalant or placebo was administered. The infusion
was discontinued if any of the following were observed: uncorrected
QT interval 550 ms or prolongation of the uncorrected QT interval
25%, HR 45 bpm lasting 30 seconds with symptoms or 40
bpm lasting 30 seconds with or without symptoms, SBP
190 mm Hg or 85 mm Hg or new requirement for inotropic
support, new bundle-branch block or QRS interval prolongation of
50%, any polymorphic ventricular tachycardia, sinus pause of 5
seconds, change in cardiac rhythm or AV conduction that compro-
mised patient safety, or any intolerable side effects. Electric cardio-
version and the administration of any additional antiarrhythmic
medication were withheld for at least 2 hours after dosing.
Patients were monitored at the study facility for a minimum of 24
hours after dosing. ECGs were recorded and vital signs were
measured at specified intervals during the screening period, the
subsequent 24 hours, on conversion to SR, at the follow-up visit
scheduled at discharge (up to day 14), and at the occurrence of a
serious adverse event (AE). Telemetry was performed before treat-
ment and continuously thereafter for at least 2 hours after dosing, and
Holter monitoring commenced at baseline and continued for 24
hours after dosing. AEs were recorded through the follow-up visit,
and serious AEs were recorded throughout the study period, which
concluded with a telephone follow-up on day 30.
Study End Points
The prespecified primary efficacy end point was the proportion of
patients with AF/AFL after CABG, valvular surgery, or both who
Randomized 2:1
(N=190)
Vernakalant (n=127)
Placebo (n=63)
AF/AFL Paents
Vernakalant (n=20)
•Spontaneous SR 
conversion, n=17
•Withdrawn consent, n=2
•Required use of 
prohibited medicaon, n=1
Placebo (n=9)
•Spontaneous SR 
conversion, n=7
•Invesgator decision, n=1
•Ineligible for study, n=1
Not Treated
Vernakalant (n=107)*
Placebo (n=54)
Vernakalant (n=100)
Placebo (n=50)
Vernakalant (n=106)
Placebo (n=54)
Vernakalant (n=100)
Placebo (n=50)
Vernakalant (n=1)*
•Withdrawn consent, n=1
AF Paents
Treated
Completed 
Study
Disconnued
Figure 1. Patient disposition. *One patient in the
vernakalant group was adjudged by the Clinical
Events Committee to be in SR before and after
treatment.
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demonstrated conversion to SR, for a minimum duration of 1 minute,
within 90 minutes of first infusion. Patients reaching this end point
were categorized as responders. The secondary efficacy end points
were the time to conversion of AF/AFL to SR among responders, the
proportion of responders with AF and their time to conversion, and
the proportion of patients with AFL who responded to treatment and
their time to conversion.
Exploratory analyses included the proportion of all responders
who required a single dose of study drug to demonstrate conversion,
the proportion of responders who remained in SR at hour 24 and day
7, the proportion of patients with at least 1 arrhythmia symptom at
each scheduled assessment and the proportion of patients who
reported each symptom at each assessment, and the influence of
baseline and demographic characteristics, including type of surgery,
on the primary end point.
All 12-lead ECG recordings were sent to a central ECG laboratory
for analysis and interpretation. All 12-lead ECGs and Holter monitor
recordings were reviewed by members of a Clinical Events Com-
mittee, who were blinded to treatment, to determine the baseline
arrhythmia and to assess conversion to SR. Safety was monitored by
a data safety and monitoring board.
Statistical Analysis
All statistical tests were 2-sided and conducted at the 0.05 signifi-
cance level. All patients in each treatment group who received any
amount of study drug were analyzed for efficacy and safety.
It was anticipated that a total of approximately 210 subjects would
be randomly assigned (140 to vernakalant and 70 to placebo) in this
clinical trial. Assuming a spontaneous conversion rate of 15%, this
would provide 178 evaluable patients. Assuming a placebo response
rate of 35%, the proposed sample size would provide 84% power to
detect a minimum difference between placebo and vernakalant of
23.5% (ie, a vernakalant response rate of 58.5%). This was based on
a 2-sided 2 test with a 5% significance level.
Demographics and baseline characteristics were compared using a
1-way ANOVA with a fixed effect for treatment for continuous
variables and a Fisher exact test for categorical variables. The
primary end point analysis was based on the Cochran-Mantel-
Haenszel test stratified by country. Logistic regression was used to
investigate the effect of various baseline and demographic charac-
teristics on the primary end point. For the secondary end points, the
Kaplan–Meier method was used to summarize the time to conversion
and the log-rank test was used to compare the distributions. Com-
parisons of the proportion variables for the secondary end points
were conducted using the same methods as used for the primary end
point. The Kaplan–Meier method was used to determine the propor-
tion of patients who remained in SR at hour 24 and day 7. A Fisher
exact test was used to summarize and compare the proportion of
patients reporting AF/AFL symptoms at various time points. Anal-
ysis of ECG intervals at each time point was based on an analysis of
covariance with treatment as a factor and baseline as a covariate. The
probability values reported are raw unadjusted probability values,
which do not account for multiplicity.
Results
Study Population
From June 2004 to February 2007, a total of 190 patients
were randomly assigned to either vernakalant or placebo
(Figure 1). Twenty-nine patients did not receive study drug,
including 24 patients (7 placebo and 17 vernakalant) who
spontaneously converted to SR before treatment. Of the other
5 patients, 2 patients assigned to vernakalant withdrew
consent and 3 patients (1 vernakalant and 2 placebo) violated
inclusion or exclusion criteria. Accordingly, 161 patients (54
placebo and 107 vernakalant) received treatment and were
included in the efficacy and safety analyses. Of the 161
patients treated, 150 had AF and 10 had AFL at randomiza-
tion. One patient who was assigned to the vernakalant group
was later adjudged by the Clinical Events Committee to be in
SR before and after treatment.
The 2 treatment groups did not differ significantly in
baseline demographic or clinical characteristics (Table 1).
Among patients in whom left ventricular ejection fraction
(LVEF) was known, the majority in both groups had a normal
LVEF. Most patients had undergone CABG surgery.
Efficacy
The primary end point, conversion of AF/AFL to SR for a
minimum duration of 1 minute within 90 minutes of first
infusion, was achieved in 44.9% (48 of 107) and 14.8% (8 of
54) of patients given vernakalant and placebo, respectively
(P0.001) (Figure 2). In patients with AF at baseline, 47%
Table 1. Baseline Demographic and Clinical Characteristics
Treatment Group
Characteristic
Placebo
(n54)
Vernakalant
(n107)
Men 40 (74.1) 81 (75.7)
White 50 (92.6) 101 (94.4)
Age, y 67.86.4 68.37.7
Surgery type
CABG 37 (68.5) 71 (66.4)
Valvular 10 (18.5) 28 (26.2)
Both 7 (13.0) 8 (7.5)
Left atrial and ventricular
measurements
LVEF 50%* 12 (30.8) 31 (36.0)
Left atrial diastolic
dimension
42.96.8 42.06.6
Arrhythmia
AF 50 (92.6) 100 (93.5)†
AFL 4 (7.4) 6 (5.6)†
Hypertension‡ 40 (74.1) 72 (67.3)
Ischemic heart disease‡ 45 (83.3) 84 (78.5)
Heart failure‡ 15 (27.8) 36 (33.6)
Concomitant therapy
Any rate control 38 (70.4) 71 (66.4)
-Blockers 38 (70.4) 64 (59.8)
Calcium channel blockers 3 (5.6) 7 (6.5)
Digitalis glycosides 3 (5.6) 9 (8.4)
Any rhythm control
Class I antiarrhythmics§ 0 0
Class III antiarrhythmics 3 (5.6) 4 (3.7)
Data are presented as n (%) or meanSD.
*Among patients in whom LVEF was known.
†One patient given vernakalant was adjudged by the Clinical Events
Committee to be in SR before and after treatment.
‡Derived from verbatim terms in medical history after study database was
locked and unblinded.
§Class I antiarrhythmics included disopyramide, flecainide, procainamide,
propafenone, and quinidine.
Class III antiarrhythmics included amiodarone, dofetilide, ibutilide, and
sotalol.
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(47 of 100) of patients given vernakalant demonstrated
conversion to SR, whereas only 14% (7 of 50) of patients
given placebo did so (P0.001). Of the patients with AFL at
baseline, none of the 6 given vernakalant and 1 of the 4 given
placebo demonstrated conversion to SR.
Prespecified subgroup analyses by surgery type revealed
no significant differences in responder rates between patients
who underwent CABG surgery and those who underwent
valvular surgery (Table 2). There was a significant difference
in responder rates between vernakalant and placebo in pa-
tients who underwent CABG surgery alone (34/71 [47.9%]
versus 5/37 [13.5%], P0.002). There was no effect of age,
sex, LVEF, or left atrial diastolic dimension on the probabil-
ity of conversion to SR. Patients given vernakalant who
received rate-control medications, however, were more likely
to demonstrate conversion to SR than were patients who did
not receive rate-control medications (22/41 [53.7%] versus
26/66 [39.4%], P0.027).
AF-to-SR conversion with vernakalant was rapid, with a
12.4-minute median time to conversion (Figure 3). Among
patients with AF/AFL who responded to treatment with
vernakalant, the median time to conversion was 12.3 minutes
(range, 0.5 to 57.1 minute). In addition, most patients (75%)
who responded to vernakalant demonstrated conversion to SR
with a single dose of vernakalant. Excluding those with
missing data, 60% of the 48 patients with AF/AFL who
responded to vernakalant were in SR at 24 hours and 57%
were in SR at day 7; only 3 responders who reverted back to
AF or AFL did so within 2 hours.
Regarding AF/AFL symptoms at minute 90, significantly
fewer patients given vernakalant compared with placebo had
rapid heartbeats (15.9% versus 46.3%, respectively,
P0.001), palpitations (16.8% versus 44.4%, P0.001), and
irregular pulse (22.4% versus 42.6%, P0.01). These results
are consistent with the greater proportion of patients who
received vernakalant that were in SR at minute 90.
Safety
Serious AEs were reported for 9.3% (10 of 107) and 11.1% (6
of 54) of patients given vernakalant and placebo, respec-
tively. Within 24 hours of dosing, 2 serious AEs occurred in
patients who received vernakalant (and were considered drug
related) and none occurred in patients given placebo. One
patient who demonstrated conversion to SR had hypotension
(arterial blood pressure of 49/39 mm Hg) 3 minutes after
receiving 1 partial dose of vernakalant. This patient was
treated with intravenous fluids and norepinephrine, and the
event resolved 3 minutes later. Another patient had complete
AV block (after conversion) during the first infusion of
vernakalant. External pacing through an epicardial wire
(placed at the time of surgery) was initiated, and the patient
recovered 12 minutes later. There were no deaths reported in
this study.
Treatment-emergent AEs occurring within 24 hours of
study drug administration occurred in 38.3% (41 of 107) and
31.5% (17 of 54) of patients who received vernakalant or
placebo, respectively. Of these, the most common events
were AF (vernakalant, 8.4%; placebo, 9.3%) and nausea
(vernakalant, 5.6%; placebo, 3.7%). Three patients in the
vernakalant group (and none in the placebo group) discon-
tinued study drug, 1 each due to hypotension (described
above), complete AV block (described above), and right
bundle-branch block.
It was not surprising that in this population, a small
proportion of patients with AF in both groups had AFL;
among patients with AF, 5 given vernakalant (5%) and 2
given placebo (4%) demonstrated conversion to AFL, all
within 1 hour of infusion. Two of the patients given ver-
nakalant and 1 given placebo later converted to SR.
Figure 2. Success rates in the overall AF/AFL population and
among patients with AF.
Table 2. Treatment-Associated Conversion of AF/AFL to SR by
Surgery Type
Surgery
Type
Placebo,
n/N (%)
Vernakalant,
n/N (%)
Treatment Difference
(Vernakalant/Placebo),
% (95% CI)
P
Value
CABG 5/37 (13.5) 34/71 (47.9) 34.4 (18.4–50.4) 0.002
Valvular 2/10 (20.0) 10/28 (35.7) 15.7 (14.8 to 46.2) 0.562
CABG and
valvular
1/7 (14.3) 4/8 (50.0) 35.7 (7.6 to 79.0) 0.088
CI indicates confidence interval.
Figure 3. Cumulative responder percentage based on time after
the start of treatment among patients with AF.
Kowey et al Vernakalant in Post–Cardiac Surgery Arrhythmia 655
 by guest on January 14, 2017
http://circep.ahajournals.org/
D
ow
nloaded from
 
In the first 2 hours and 24 hours after the start of dosing,
the incidence of all ventricular arrhythmia events was similar
in both treatment groups (Table 3), including 4 patients given
vernakalant who developed nonsustained ventricular
tachycardia in the first 2 hours, lasting 3 to 12 beats. The
nonsustained polymorphic ventricular tachycardias did not
resemble torsades de pointes morphologically. In addition,
there were no marked increases in QT interval or typical
variations in R-R interval (pause-dependent sequences) dur-
ing the arrhythmia initiation to suggest torsades de pointes.
These arrhythmias were identified by Holter monitoring and
12-lead ECG data, and none were reported as AEs. Over the
same observation periods, bradycardia events occurred more
often in the vernakalant group (Table 3). Few patients had an
HR 40 bpm, and the incidence of an HR 40 bpm was
similar among the vernakalant and placebo groups. Although
the incidence of hypotension events was similar among
treatment groups, more patients given vernakalant had a SBP
90 mm Hg. There were no cases of torsades de pointes,
sustained ventricular tachycardia, or ventricular fibrillation in
either treatment group.
Vernakalant and ECG Parameters
The meanSD HR among all patients given vernakalant fell
from 12226 bpm at baseline to 10523 bpm 10 minutes
after initiation of treatment. This was largely accounted for by
the reduction in HR among patients who demonstrated
conversion to SR (Figure 4A). Among those given ver-
nakalant who remained in AF or AFL, the decrease in HR,
although significantly different from placebo through minute
50 and remaining essentially the same through hour 2, was
smaller (Figure 4A). In patients who demonstrated conver-
sion to SR with vernakalant, from baseline to the end of the
first infusion, the mean QRS interval increased from
101.014.9 to 106.616.1, and the mean Fridericia-
corrected QT interval (QTcF) increased from 407.325.1 to
426.030.4 ms. The mean Bazett-corrected QT interval
(QTcB) decreased from 454.627.3 ms to 445.634.8 ms.
To avoid the potential confounding effects on QRS and QT
intervals caused by reductions in HR after conversion to SR,
the effects of vernakalant on ECG parameters were also
compared with placebo in patients who remained in AF or
AFL. Among nonresponders, vernakalant prolonged QRS
intervals from a baseline value of 99.712.2 ms to a peak of
110.022.2 ms at the end of second infusion. Increases from
baseline in QRS intervals were significantly greater with
vernakalant than with placebo at all times from 10 minutes to
2 hours (Figure 4B). Maximum increases from baseline in
mean QTcB and QTcF with vernakalant in patients who
remained in AF/AFL occurred at the end of first infusion, and
these increases were significantly greater with vernakalant
than with placebo from minutes 10 to 50 (Figure 4C and D).
The minute-90 QTcF difference from baseline was also
significant.
Among the 93 patients given vernakalant and 44 given
placebo, with QT measurements taken at baseline and at 10
minutes, 28% and 7%, respectively, had a QTcB 500 ms at
the end of first infusion. If patients with baseline QTcB500
ms are excluded, these percentages fall to 24% with ver-
nakalant and 2% with placebo. Within 90 minutes, the
percentage of patients with a QTcB 500 ms in the 2
treatment groups was similar (7% vernakalant versus 10%
placebo for all patients; 4% and 8%, respectively, for patients
with baseline QTcB 500 ms). For QTcF, 3% of patients
given vernakalant and none of the patients given placebo had
values 500 ms at the end of first infusion, all of whom had
baseline values 500 ms. Within 90 minutes, none of the
patients in either treatment group had QTcF 500 ms.
Table 3. Ventricular Arrhythmia Events, Bradycardia Events, and Hypotension Events in the First 24 Hours
0–2 h After Dosing 2–24 h After Dosing After Dosing
Placebo
(n54)
Vernakalant
(n107)
Placebo
(n54)
Vernakalant
(n107)
Placebo
(n54)
Vernakalant
(n107)
Event, n (%)
Any ventricular arrhythmia
event*
2 (3.7) 5 (4.7) 7 (13.0) 16 (15.0) 9 (16.7) 19 (17.8)
Torsades de pointes 0 0 0 0 0 0
Ventricular tachycardia† 0 4 (3.7) 7 (13.0) 16 (15.0) 7 (13.0) 18 (16.8)
Ventricular fibrillation 0 0 0 0 0 0
Other rhythm‡ 2 (3.7) 2 (1.9) 0 1 (0.9) 2 (3.7) 3 (2.8)
Any bradycardia event§ 1 (1.9) 10 (9.3) 1 (1.9) 7 (6.5) 2 (3.7) 15 (14.0)
Any HR 40 bpm on
Holter
1 (1.9) 4 (3.7) 0 0 1 (1.9) 4 (3.7)
Any hypotension event 9 (16.7) 14 (13.1) 9 (16.7) 13 (12.2) 13 (24.1) 23 (21.5)
SBP 90 mm Hg 0 6 (5.6) 0 3 (2.8) 0 8 (7.5)
*Derived from AEs, Holter monitoring, and 12-lead ECGs. Patients may have had 1 event.
†Wide-complex beats (3 beats) with an HR 100 bpm.
‡Other rhythm includes aberrant pair, ventricular pair, and ventricular bigeminus.
§Incidence based on combined analysis of AEs, 12-lead ECGs, including sinus bradycardia (HR 60 bpm) and Holter monitoring.
Incidence based on combined analysis of AEs and vital signs assessments (SBP 90 mm Hg, SBP decrease from baseline
30 mm Hg, diastolic blood pressure decrease 15 mm Hg).
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Discussion
After cardiac surgery, postoperative AF is still common
despite use of -blockers and other measures of prophylaxis,
and it often develops in patients with comorbidities predis-
posing to prolonged hospitalization.7 The incidence of post-
operative AF is also rising, possibly due to the increasing age
of cardiac surgical patients.2 According to recent guidelines
for AF management, it is reasonable to restore SR in patients
who have AF after cardiac surgery (level of evidence: B) with
pharmacological treatments, which are more commonly used
than electric cardioversion.2,7,19 Moreover, several studies
have demonstrated an increased risk of stroke in patients after
CABG.20,21 Therefore, anticoagulation is appropriate when
AF persists 48 hours or longer.2 Anticoagulation after cardiac
surgery can also be hazardous, making prompt restoration of
SR all the more reasonable.
Despite the prevalence and importance of AF secondary to
cardiac surgery, few randomized, placebo-controlled studies
have evaluated the efficacy of antiarrhythmic agents for
restoring SR in patients after cardiac surgery.13,14 Ibutilide
was shown to be more effective than placebo in converting
post–cardiac surgery AF or AFL to SR; in that study,
however, polymorphic ventricular tachycardia, both sustained
and nonsustained, was reported in approximately 2% of
patients, which has limited its usefulness.14 Amiodarone is
frequently used intravenously, but evidence to support its
efficacy for this indication is scarce. Furthermore, clinicians
may be reluctant to use electric cardioversion because of the
mandate for anesthesia.
Nevertheless, it is deemed advisable by guidelines to restore
SR in patients with postoperative AF that is complicated by
significant symptoms, hemodynamic instability, or a contraindi-
cation to anticoagulant therapy.13 In all cases, the choice of drug
should be based on individual patient characteristics.13
In the present study, vernakalant was significantly more
effective in rapidly converting AF to SR in patients with
sustained AF that began 24 hours to 7 days after CABG,
valvular surgery, or both. Treatment-associated conversion
was demonstrated in 47% of vernakalant and 14% of placebo
patients. AF to SR conversion with vernakalant was rapid,
with a median time to conversion of 12 minutes, and 75% of
responders required only 1 dose of vernakalant. Significantly
fewer patients given vernakalant had rapid heartbeats, palpi-
tations, and irregular pulse rates compared with those given
placebo. In 6 patients with AFL at baseline, vernakalant did
Figure 4. Time course of changes from baseline in HR and QRS, QTcB, and QTcF for patients with AF/AFL given vernakalant com-
pared with patients given placebo. Data (meanSD) are shown for patients who remained in AF or AFL, except in A, which includes
vernakalant-treated patients who demonstrated conversion to SR (wide error bars).
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not convert the arrhythmia to SR. Although there were too
few patients with AFL to draw any firm conclusions in the
postoperative population, vernakalant has not proven effec-
tive in converting AFL to SR in any study to date.18
Effectiveness for AFL conversion may require more potent
IKr block, as with ibutilide.14 There were no significant
differences in treatment-associated conversion rates among
those who underwent CABG or valvular surgery alone,
although the number of patients with valvular surgery was
small.
Patients given vernakalant who remained in AF or AFL
had significant increases in QRS, QTcB, and QTcF intervals,
with the latter 2 returning to placebo levels within 2 hours. In
those who remained in AF or AFL, vernakalant also had a
small but significant HR-lowering effect, which dissipated
within 90 minutes. These observations probably are caused
by K channel blockade (which occurs predominantly in the
atria but also affects the ventricles), Na channel blockade,
and modest AV-nodal–blocking effects of vernakalant.22
Patients given vernakalant did have a higher incidence of
bradycardia events, but this probably is related to the high
rate of SR conversion with vernakalant and the subsequent
large drop in HR.
Vernakalant was well tolerated. Only 2 patients in the
vernakalant group discontinued because of serious AEs
within 24 hours of treatment; each patient recovered without
sequelae. One of these patients had hypotension during the
initial vernakalant infusion. The infusion was discontinued;
saline and norepinephrine were given and the event resolved
3 minutes after onset. Hypotension with vernakalant infusion
typically occurs during or immediately after the infusion, is
generally transient, and responds to saline.17 A similar inci-
dence of ventricular arrhythmia events was reported in the
placebo and vernakalant groups in the 24 hours after dosing,
and there were no cases of sustained ventricular tachycardia,
torsades de pointes, or ventricular fibrillation in either group.
The primary limitation of this study is the population sizes.
The total population and the CABG surgery population (67%
of the total) were sufficient for the overall analysis and the
CABG subgroup analysis. However, too few patients had
valvular surgery or both CABG and valvular surgery, so the
effect of vernakalant in those subgroups is not entirely clear.
Further study of vernakalant in these situations is warranted.
In conclusion, similar to findings from earlier phase 3 trials in
patients with AF in other settings,17,18 this study demonstrated
that vernakalant was safe and effective for AF-to-SR cardio-
version in patients after cardiac surgery.
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CLINICAL PERSPECTIVE
Atrial fibrillation (AF) occurring after cardiac surgery is common and is associated with considerable morbidity. Early
restoration of sinus rhythm is usually desirable, and pharmacological conversion is generally preferable to electrical
cardioversion in these early postoperative patients. Intravenous vernakalant, a new antiarrhythmic agent with atrial
selective properties, has been shown to be effective in rapidly and safely converting approximately 50% of patients with
new-onset AF. In this study, vernakalant demonstrated successful conversion of AF to sinus rhythm in 47% of patients with
new-onset AF after cardiac surgery. Responders converted rapidly (median time, 12 minutes). Vernakalant was ineffective
at converting a small number of patients (n6) with new-onset atrial flutter. Two serious adverse events occurred during
the initial 10-minute vernakalant infusion. One event of hypotension responded to discontinuation of the infusion,
intravenous fluids and norepinephrine, resolving in 3 minutes. The other event was complete heart block that responded
to discontinuation of the infusion and pacing through an epicardial wire (placed at the time of surgery), resolving in 12
minutes. Vernakalant does not appear to promote ventricular arrhythmia. Episodes of asymptomatic, nonsustained
ventricular runs were captured on Holter monitoring in all patients given vernakalant or placebo. There were no episodes
of torsades de pointes, ventricular fibrillation, or death. Vernakalant is potentially a safe and effective pharmacological
alternative for the conversion of AF to sinus rhythm in patients after cardiac surgery.
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